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Although chromosomal deletions and inversions are important in cancer, conventional methods for detecting DNA
rearrangements require laborious indirect assays. Here we develop fluorescent reporters to rapidly quantify CRISPR/
Cas9-mediated deletions and inversions. We find that inversion depends on the non-homologous end-joining
enzyme LIG4. We also engineer deletions and inversions for a 50 kb Pten genomic region in mouse liver. We
discover diverse yet sequence-specific indels at the rearrangement fusion sites. Moreover, we detect Cas9 cleavage
at the fourth nucleotide on the non-complementary strand, leading to staggered instead of blunt DNA breaks.
These reporters allow mechanisms of chromosomal rearrangements to be investigated.Background
Chromosomal deletions and inversions are common in
human cancers, suggesting their causal roles in tumori-
genesis [1]. In the past 2 years, the bacterial CRISPR [2]
system has been transformed into a remarkable genome-
editing tool [2–8]. The development of single-guide
RNAs (sgRNAs) [7] allows the Cas9 nuclease to be readily
targeted to specific genomic sequences with a downstream
protospacer-adjacent motif (PAM), where Cas9 generates
double-stranded DNA breaks that promote non-
homologous end-joining (NHEJ) or homology-directed
repair (HDR). NHEJ can result in indels that potentially
inactivate the target gene and HDR generally results in
precise DNA repair when guided by an exogenous donor
molecule [6]. CRISPR/Cas9 genome editing tools have
been successfully applied in many organisms, including
mouse and human cells [9, 10]. We have recently applied
CRISPR/Cas9 genome editing to repair a genetic disease
gene [11] and study cancer drivers in the mouse liver
in vivo [12]. This approach allowed one to rapidly identify* Correspondence: Zhiping.Weng@umassmed.edu; Wen.Xue@umassmed.edu
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mechanisms in mice [13–15].
Engineering chromosomal rearrangements using trad-
itional Cre-LoxP methods is technically challenging and
time consuming [16]. CRISPR/Cas9 can also be used to
model chromosomal rearrangements. Recent studies were
performed on cell lines [3, 17–25], ES cells [26], mouse zy-
gotes [27, 28], and lung cancer mouse models [16, 29];
however, detecting chromosomal rearrangements requires
a series of indirect assays such as polymerase chain reac-
tion (PCR) in single cell clones, Sanger sequencing, and
fluorescent in situ hybridization. These low throughput
assays limit the investigation of mechanisms of chromo-
somal rearrangements. Herein, we developed a fluorescent
reporter system for directly detecting CRISPR/Cas9-medi-
ated DNA inversions and deletions. We demonstrated that
CRISPR/Cas9 could induce both deletion and inversion
events in cultured cells and for a 50 kb Pten genomic
region in the liver of adult mice.Results
To develop a reporter system for visualizing chromo-
somal rearrangements, we used an inverted GFP (iGFP)
plasmid [13] to mimic intra-chromosomal inversion
(Fig. 1a). The GFP coding region was cloned in the
inverted orientation after the cytomegalovirus (CMV)
immediate-early promoter, preventing the expression ofdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 An inverted GFP reporter (iGFP) to visualize CRISPR/Cas9-mediated DNA inversion. a Schematic of iGFP. Red arrowheads indicate the Cas9
cutting sites recognized by the sgiGFP.1 and sgiGFP.2. Inversion of the GFP cassette will lead to GFP expression from the CMV promoter. PAM
sequences are underlined. Red and blue color indicate sequences flanking the predicted fusion site (indicated by ‘|’). The blue sequence in the
inverted plasmid will be reverse-complementary of the original sequence. b 293 T cells were co-transfected with 0.5 μg iGFP and 0.5 μg of two
px330 plasmids (sgiGFP.1 + 2) and imaged 24 h later. c A PCR reaction detected inversion (primers p1 + p2) from total cellular DNA. The
arrowhead indicates the expected inversion band. d Deep-sequencing identified perfect fusion and indels (insertions or deletions) at the DNA
fusion sites. Purple bars in representative IGV images (two biological replicates) indicate insertions. Position indicates basepair position in
the reference sequence. e Quantification of indels. VarFreq is the average of two replicates. 22 % of the reads mapped perfectly with
predicted reference sequence, corresponding to precise ligation of the DNA breaks. f Two sgRNAs also induced deletion between CRISPR/Cas9 cutting
sites. A PCR reaction detected deletion of the iGFP reporter (primers p1 + p3). The top bands are full length PCR products. An arrowhead indicates the
expected deletion band
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two CRISPR/Cas9-mediated DNA breaks flanking the
approximately 1.0 kb GFP cassette, we might be able to
invert the orientation of the iGFP (Fig. 1a). We designed
two sgRNAs targeting the flanking sequences (Fig. 1a
and Additional file 1: Table S1). Co-transfection of two
pX330 [30] plasmids co-expressing Cas9 and sgRNAs
(hereafter named sgiGFP.1 + 2) with the iGFP plasmid in
human 293T cells indeed led to GFP expression (Fig. 1b),
confirming that cells can ligate distant DNA breaks from
inverted DNA fragments [21].
To confirm that GFP expression was caused by inver-
sion of the iGFP cassette, we designed PCR primers at the
CMV promoter and the GFP N-terminal region, which
could only amplify the inverted iGFP (Fig. 1a). PCR de-
tected a band of the expected size in sgiGFP-transfected
cells (Fig. 1c), suggesting that CRISPR/Cas9 can medi-
ate DNA inversion between two sgRNA-directed cut-
ting sites. To gain insights into how accurately these
cells ligated the distant DNA breaks, we performeddeep sequencing on the PCR band shown in Fig. 1c.
We performed each experiment in two biological repli-
cates, and obtained 1.2 and 0.6 M reads for the two
replicates of sgiGFP.1 + 2 transfection, respectively. We
predicted the reference sequence with an inverted iGFP,
assuming that the Cas9 cutting site is 3 nucleotides (nt)
upstream of the PAM (Additional file 2: Figure S1; see
Additional file 1: Table S3 for reference sequences). We
found that 96 % of the sequencing reads mapped to the
reference (see Additional file 1: Table S4 for sequencing
and mapping statistics). Thousands of reads mapped
perfectly to the predicted fusion site, corresponding to
a frequency of 22.2 % for precise ligation of the DNA
breaks assuming that both of the cutting sites are 3 nt
upstream of the PAM [2]. Other reads mapping to the
fusion site revealed ‘+G’ (55.4 % frequency) and ‘+GG’
(7.5 %) insertions at position 235, as well as ‘–A’ (12.1 %)
and other lower frequency deletions at position 236 of the
reference (Fig. 1d, e and Table 1). The indel frequencies
from the two biological replicates were in almost perfect
Table 1 Summary of indels detected at the predicted inversion or deletion fusion sites
Name Replicate Position Ref Indel Reads supporting ref Reads supporting indel VarFreq P value
iGFP 1 235 A +G 2631 4158 55.31 % 0
236 G -A 1786 257 11.83 % 7.64E-78
235 A +GG 2631 580 7.72 % 4.36E-181
236 G -AC 1786 50 2.30 % 1.67E-14
236 G -ACT 1786 35 1.61 % 4.61E-10
iGFP 2 235 A +G 2662 4152 55.50 % 0
236 G -A 1852 276 12.40 % 6.55E-84
235 A +GG 2662 548 7.33 % 3.92E-170
236 G -AC 1852 35 1.57 % 4.63E-10
LoxP-O 1 304 A +T 2278 4386 64.55 % 0
305 T -A 1590 42 2.51 % 3.88E-12
302 T -TA 7165 144 1.96 % 5.96E-35
303 T -A 6941 91 1.29 % 3.68E-20
LoxP-O 2 304 A +T 2267 4429 64.89 % 0
305 T -A 1595 48 2.87 % 6.36E-14
302 T -TA 7186 140 1.90 % 8.19E-34
303 T -A 6974 82 1.16 % 9.96E-18
LSL 1 88 T +A 1804 2533 56.19 % 0
89 A -T 1403 41 2.74 % 7.43E-12
87 G -T 4896 89 1.72 % 2.15E-22
87 G -TA 4896 87 1.68 % 8.00E-22
86 C -GTATAAT 5204 78 1.47 % 2.49E-18
89 A -TAAT 1403 15 1.00 % 2.51E-04
LSL 2 88 T +A 1708 2602 58.47 % 0
89 A -T 1353 41 2.83 % 7.36E-12
87 G -TA 4820 95 1.85 % 4.07E-24
87 G -T 4820 87 1.69 % 7.96E-22
86 C -GTATAAT 5144 63 1.20 % 3.26E-14
89 A -TAAT 1353 17 1.17 % 6.93E-05
Pten-deletion 1 453 A +C 6477 1110 14.16 % 0
453 A -T 6477 79 1.01 % 9.97E-18
Pten-deletion 2 453 A +C 6607 1039 13.33 % 2.08E-314
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by the high frequencies of indels. Careful inspection of the
sequences surrounding the cutting sites revealed that the
‘+G’ and ‘+GG’ insertions could have also been caused by
alternative cutting sites of iGFP.1, that is, instead of cut-
ting at 3 nt upstream of the ‘NGG’ PAM, these sequencing
reads were consistent with cutting at 4 nt and 5 nt up-
stream of the PAM (Fig. 1a). It has been reported that
Cas9 can cleave the complementary DNA strand at 3 nt
and the non-complementary DNA strand within 3–8 nt
upstream of the PAM, followed by trimming of the 3′ end
by exonuclease activity [7]. Furthermore, if we assume that
the cutting site of iGFP.1 is most frequently located at4 nt upstream of the PAM, all the deletions can also be ex-
plained by the cutting sites of iGFP.2 being 4 nt, 5 nt, or
6 nt upstream of the PAM. Further studies are required to
investigate whether CRISPR/Cas9 can induce DNA breaks
at varying distances upstream of the PAM and contribute
to repair of fusion sites.
CRISPR/Cas9 has also been implicated in mediating
deletions between DNA break sites [21]. We designed
PCR primers that could detect deletions between the
two sgRNA sites in the iGFP reporter (Fig. 1a). A PCR
reaction detected a lower band of expected deletion size
only in 293T cells co-transfected with sgiGFP.1 + 2
(Fig. 1f ), indicating a deletion of the iGFP reporter.
Li et al. Genome Biology  (2015) 16:111 Page 4 of 11These results confirmed that both inversion and deletion
can occur between CRISPR/Cas9 cutting sites [21].
Because we used transfection of the iGFP reporter
plasmids, our system may report iGFP inversion in a
subset of plasmids, which could result from CRISPR/
Cas9 interactions with weak PAMs. The iGFP plasmid
also harbors two LoxP Orange (LoxP-O) sites for Cre
recombinase-mediated inversion [13] (Additional file 2:
Figure S2a). Because LoxP-O sites do not contain an
‘NGG’ PAM sequence, we designed a single sgRNA tar-
geting a weak ‘NAG’ PAM [3] in the LoxP-O sites (see
Additional file 1: Table S3 for sequences). Indeed
sgRNA.LoxP-O induced GFP expression in 293T cells,
albeit at a much lower level than sgiGFP.1 + 2 with the
‘NGG’ PAM (Additional file 2: Figure S2b). A PCR re-
action detected a band of the expected size of sgiGFP
in sgLoxP transfected cells (Additional file 2: Figure
S2c). When we sequenced the PCR band, we observed
that 64.7 % of fusion site mapping reads harbored a ‘T’
insertion (Additional file 2: Figure S2d, e; Table 1).
Again, the insertion may be caused by the downstream
cutting site being 4 nt upstream of the ‘AAG’ PAM.
We then used mouse 3T3 cells stably expressing a sin-
gle copy of iGFP introduced via a retroviral vector to
quantify iGFP inversion at a chromosomal locus [13]Fig. 2 CRISPR/Cas9 mediates deletion and inversion of a chromosomal iGF
reporter. LTR is the long terminal repeat of the MSCV retroviral vector. Arro
plasmids inversion sgiGFP.3 and sgiGFP.5 (sgiGFP) or control sgRNAs and ima
cells. The averaged percentage of GFP+ cells is indicated (n = 3). d A PCR reac
expected inverted band. e A PCR reaction detected deletion bands (arrowhea
31.0 ± 7.4 % (n = 2)(Fig. 2a). Co-transfection of two sgRNAs sgiGFP.3 and
sgiGFP.5 (hereafter named sgiGFP) targeting retroviral
iGFP flanking sequences led to 23.6 ± 4.1 % GFP+ cells
(Fig. 2b, c). Because the cells only had one copy of genomic
iGFP, GFP+ cells were used to estimate the percentage of
cells that underwent iGFP inversion. Importantly, our
chromosomal iGFP reporter method offers a simple and
fast assay to quantify cells with CRISPR-mediated gen-
omic inversions and bypasses the laborious single cell
cloning used in the literature [21]. In cells transfected with
sgiGFP, PCR reactions detected bands of the expected
sizes using primers that would detect inversion or deletion
between sgRNA cutting sites (Fig. 2d, e), confirming that
CRISPR/Cas9 can mediate both events [21]. By quantify-
ing the deletion PCR bands (Fig. 2e), we estimated that
the deletion PCR bands represent 31.0 ± 7.4 % of total
PCR products. Although the 400 bp deletion PCR prod-
ucts presumably have higher PCR efficiency than the
1.4 kb full length PCR products, these numbers are con-
sistent with a recent study showing approximately 30 %
deletion efficiency of a 1.3 kb genomic region in mouse
MEL cells [21].
To monitor CRISPR/Cas9-mediated deletions, we de-
veloped a Lox-STOP-Lox reporter (hereafter named
LSL), whereby an approximately 2.7 kb STOP cassetteP reporter. a Schematic of mouse cells harboring a chromosomal iGFP
ws denote PCR primers. b Cells were co-transfected with pX330
ged 72 h later. c FACS analysis to detect the population of GFP-positive
tion detected inversion from genomic DNA. An arrowhead indicates the
d) from genomic DNA. The percentage of the deletion band intensity is
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porter, a self-cleaving 2A peptide, and luciferase (Fig. 3a).
We designed a sgRNA to the LoxP sites with a weak
‘NAG’ PAM. Induction of both tdTomato and luciferase
signals was observed in 293 T cells co-transfected with
LSL and sgLoxP, indicating that the STOP cassette was
removed by CRISPR/Cas9 (Fig. 3b, c). A PCR reaction
confirmed that introduction of sgLoxP led to deletion
between the LoxP sites (Fig. 3d). We performed TOPO
cloning and Sanger sequencing on the deletion PCR
band in Fig. 3d and detected error-free fusion and fu-
sions with small indels (Fig. 3e). We further performed
deep sequencing on the deletion PCR band in two bio-
logical replicates (Fig. 3f, g). Sequencing reads revealedFig. 3 Modeling CRISPR/Cas9-mediated DNA deletion using a Lox-STOP-Lo
reporter plasmid (LSL). Purple triangles indicate the LoxP sites recognized b
red arrowhead indicates the Cas9 cutting site. The red arrows indicate the
‘NAG’ PAM in the LoxP sequence is in bold. b 293T cells were co-transfecte
of luciferase bioluminescence was quantified. Error bars are the standard d
arrowhead indicates the expected deletion band. e PCR samples were puri
f Deep sequencing. Representative IGV images of two biological replicates.‘+A’ (57.3 %), ‘–T’ (2.8 %), and other lower frequency
indels, along with a 34 % frequency for error-free fusion.
Both ‘+A’ and ‘–T’ indels could be due to either NHEJ-
mediated indels or by one cutting site being 4 nt up-
stream of the PAM. These results suggest that the
CRISPR/Cas9 system can mimic the Cre recombinase in
deleting sequences between LoxP sites, and that we have
established a platform for monitoring CRISPR/Cas9-me-
diated deletions.
Our fluorescent reporters allow rapid detection of
DNA rearrangement events, which could facilitate study-
ing mechanisms of CRISPR-mediated DNA rearrange-
ments in cells with defined mutations in DNA repair
pathways. The non-homologous end-joining (NHEJ)x (LSL) reporter. a Schematic of the LSL cassette (STOP is 2.7 kb) of a
y sgLoxP. The asymmetric 8 bp sequence of LoxP is underlined. The
location and direction of forward and reverse primers, respectively. The
d with 0.3 μg LSL and 0.5 μg sgLoxP and imaged 48 h later. c The level
eviation (s.d., n = 3). d A PCR reaction-detected deletion. An
fied, TOPO cloned, and sequenced. Red nucleotides indicate indels.
g Count of indels
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breaks to generate chromosomal rearrangements [31].
We asked whether this pathway was required for the re-
pair of CRISPR/Cas9-mediated inversions. We used LIG4
−/− HCT116 cells [31] that are deficient in canonical NHEJ
and severely impaired in chromosomal translocations.
LIG4 (Ligase IV) encodes a DNA ligase that joins double-
strand DNA breaks during NHEJ [31]. Upon co-
transfection of iGFP and sgRNA.1 + 2, we observed that
GFP inversion was abolished in LIG4−/− cells compared to
LIG4 wild type cells (13.3 ± 0.8 % GFP in wild type
HCT116 cells and 0.3 ± 0.1 % GFP in LIG4−/− HCT116
cells, p = 4 × 10−6, Fig. 4a, c) at equal transfection effi-
ciency (Fig. 4b). These results suggest that CRISPR/Cas9-
mediated inversion is LIG4-dependent in human cells.
Our cell culture data suggest that CRISPR can mediate
both chromosomal deletions and inversions (Figs. 1 and
2). To explore whether CRISPR can mediate both events
in vivo, we targeted a 50 kb region of the mouse genome
encompassing the first four exons of the Pten [32] gene,
a region frequently deleted in liver cancer [33] (Fig. 5a, b).
We co-delivered two pX330 plasmids with two sgRNAs
targeting non-coding Pten regions (sgPten.a + b) to five
adult FVB mice by hydrodynamic tail vein injection [12], a
method that delivers DNA to hepatocytes for transient ex-
pression. As controls, we injected an sgRNA targeting
GFP (sgGFP), sgPten.a alone or sgPten.b alone in five
mice per group. Two weeks later, immunohistochemistry
identified hepatocytes with negative Pten staining in liverFig. 4 iGFP inversion is LIG4-dependent in human cells. a HCT116 wildtype
and sgiGFP.1 + 2. Top: microscopic images. Bottom: FACS analysis of GFP p
cells transfected with tdTomato plasmid. c Quantification of GFP+ cells in (asections in sgPten.a + b mice but not in sgGFP, sgPten.a
alone or sgPten.b alone groups (Fig. 5c, d and Additional
file 2: Figure S3). Using PCR primers to detect chromo-
somal rearrangements (Fig. 5a), we observed deletion and
inversion PCR products between the sgRNA target sites in
genomic DNA from sgPten.a + b mice but not from
sgGFP mice (Fig. 5e, f ). We performed deep sequencing
on the deletion and inversion PCR products, each from
two mice. Because the deletion PCR bands were relatively
weak, we did not perform gel extraction prior to sequen-
cing (we performed gel extraction for all other deep se-
quencing samples in this study). We obtained 1 M and
1.4 M reads for the two deletion samples, among which
54 % of the reads mapped to the predicted reference se-
quence with the deletion and 42 % reads mapped to the
mouse genome (Additional file 1: Table S4). Reads that
mapped to the fusion site revealed the most frequent indel
to be ‘+C’ (approximately 13.8 %) with a very high fre-
quency (85.7 %) of error-free fusion (Fig. 5g, i; Table 1).
Moreover, the ‘+C’ insertion could be caused by the cut-
ting site of sgPten.b being 4 nt upstream of the PAM.
We also obtained high quality deep sequencing data for
the inversion PCR bands (2.1 M and 1.9 M reads for
two mice, of which 99 % mapped to the predicted refer-
ence sequence). Strikingly, almost all reads that mapped
to the fusion site did so perfectly, and we did not detect
any indel with greater than 1 % frequency (Fig. 5h).
Because CRISPR/Cas9 has known off-target effects
[34], we measured the indel rates at the top four(WT) or HCT116 LIG4−/− cells were co-transfected with iGFP reporter
ositive cells. b Equal transfection efficiency in HCT116 WT and LIG4−/−
). Error bars are the s.d. (n = 3)
Fig. 5 CRISPR/Cas9-mediated deletion and inversion of the Pten genomic region in mouse liver. a Schematic of deletion or inversion of a 50 kb
Pten region on mouse chromosome 19. b Two pX330 plasmids expressing Cas9 and sgRNAs (sgPten.a + b) were co-delivered to mice via hydrodynamic
injection. Red triangles indicate the sites recognized by sgPten.a and sgPten.b. The black arrow denotes the promoter. Liver tissue was analyzed 2 weeks
later. c Quantification of Pten immunohistochemistry (n = 5 mice). Error bars are the s.d. d Pten-negative hepatocytes (arrows) were detected via
immunohistochemistry. e, f A PCR reaction detected deletion (e) or inversion (f) of the targeted Pten region. g, h Deep sequencing of PCR
bands detected approximately 14 % indel at the predicted deletion re-ligation site. We did not detect any indels with >1 % frequency at the
predicted inversion repair site. Shown are representative IGV images of two biological replicates. i Quantification of deletion indels in (g)
Li et al. Genome Biology  (2015) 16:111 Page 7 of 11predicted off-target sites of sgPten.a. In mouse 3T3 cells
transfected with sgPten.a, the surveyor nuclease assay
detected indels at the on-target Pten site but not at any
of the assayed off-target sites (Additional file 2: Figure S4).
These results indicate that CRISPR/Cas9 can mediate
chromosomal inversion and deletion in the mouse liver
with high specificity.
While the canonical view is that S. pyogenes Cas9 gener-
ates a blunt end at 3 nt upstream of PAM [6], our deep se-
quencing data suggest non-canonical Cas9 cleavage
(Fig. 1e). To map the Cas9 cleavage site of sgiGFP1, we
performed in vitro Cas9/sgRNA cleavage assay using Cas9
protein and in vitro T7 transcribed sgiGFP.1 RNA
(Fig. 6a–c). By sequencing the ends of the cleaved iGFP
plasmid, we observed that Cas9 cleaves the complemen-
tary DNA strand at 3rd nt (Fig. 6c). Interestingly, cleavage
of Cas9 could occur at 4 nt upstream of PAM on the non-
complementary strand (Fig. 6c and Additional file 2:Figure S5), suggesting that Cas9 can generate staggered
DNA breaks with 1 nt 5′ overhang for some sgRNA. Our
finding confirmed an earlier study [7] that Cas9 cuts at
non-canonical positions (4–6 nt upstream of PAM instead
of 3 nt upstream). Importantly, a fourth nucleotide inser-
tion upstream of PAM is frequently observed at Cas9 tar-
get site in Pten, p53, and Ctnnb1 genes in mouse cells
following NHEJ (Fig. 6d and Additional file 2: Figure S6)
[12], which is consistent with end filling and ligation of a
staggered DNA break. This surprising feature of Cas9
cleavage can elucidate how CRISPR-mediated DNA
breaks are repaired in cells. Further studies are required to
investigate how non-canonical CRISPR/Cas9 cleavage
contributes to DNA repair.
Discussion
In summary, we have developed fluorescent reporter-based
systems to quantitatively report CRISPR/Cas9-mediated
Fig. 6 Cas9 can generate staggered DNA breaks. a–c Biochemical mapping identified non-canonical Cas9 cleavage sites. a Schematic of Cas9
cleavage assay. ‘cct’ is PAM. b In vitro cleavage of BamHI linearized or circular DNA by Cas9 protein and purified sgRNA. The expected cleavage
products are 5 + 1 kb for linearizd iGFP plasmid. The size shift (arrowhead) of circular iGFP plasmid indicates Cas9 cleavage. c Sequencing analysis
of cleaved products. Red arrowheads indicate Cas9 cleavages sites on two DNA strands. The 3′ terminal A or T (asterisks), caused by artifacts of
sequencing reactions, indicate termination of primer extension and the position of the Cas9 cleavage sites [7]. The circled ‘G’ in sequencing trace
indicates that Cas9 can cut at fourth nt on the non-complementary strand. The downstream weak ‘G’ peak overlapping with ‘A’ implies fifth nt
cleavage. d Fourth nucleotide insertion of ‘C’ nucleotide* (+C) was frequently observed at sgPten target site after single sgRNA transfection in
mouse cells. Indel representation is the ratio of selected indel versus all observed indels. Arrowhead indicates predicted Cas9 target sites. The
position of the most abundant insertion (red arrow) is indicated in the target sequence. PAM sequence is in blue
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depth sequence characterization of the deletion and in-
version breakpoints, shown the suitability of using a less
favorable ‘NAG’ PAM to induce deletions, and shown a
dependency for LIG4 in the CRISPR/Cas9-mediated in-
versions. A similar approach has recently been used to
excise a mTmG (Tomato and GFP) two-color fluores-
cent Cre reporter allele [35]. These reporter systems can
be used to identify the DNA repair enzymes required
for the rearrangement and improve our understanding
of the role of DNA repair pathways in genomic rearrange-
ments. For example, our findings indicate that the NHEJ
enzyme LIG4 is required for the CRISPR/Cas9-mediated
inversion events; the first time that this enzyme has been
implicated in inversion rearrangements outside of V(D)Jrecombination. The role of LIG4 in mediating the rear-
rangements and the application of CRISPR-Cas9 to induce
inversions and deletions in cells and in mice have been re-
ported by recent studies [16, 19, 21, 31].
We successfully deleted or inverted a 50 kb region in
the mouse genome in a subset of hepatocytes, and al-
though further experiments are required to test the upper
size limit that can be accomplished by this technology, this
observation is certainly encouraging. Future studies are
also needed to characterize potential chromosomal rear-
rangements induced by off-target Cas9 cutting [36].
We observed that CRISPR/Cas9 cutting sites were either
re-ligated perfectly or with small indels, which is con-
cordant with recent studies using CRISPR/Cas9 to induce
chromosomal rearrangements in cells [19, 21]. We tested
Li et al. Genome Biology  (2015) 16:111 Page 9 of 11three inversions and two deletions, each with two bio-
logical replicates. Even though the indels were dominated
by one-nucleotide insertions, we observed the insertion of
all four types of nucleotides. This can be explained by ei-
ther NHEJ-induced errors or by one CRISPR/Cas9 cutting
site being 4 nt upstream of the PAM, at least on one DNA
strand. These results are particularly striking given the
prevailing notion that the S. pyogenes Cas9 cutting site is
almost invariably located at 3 nt upstream of the PAM [2].
In our study, the identity and frequency of the types of nu-
cleotide being inserted are reproducible between bio-
logical replicates. Notably, the LSL deletion and LoxP-O
inversion constructs used similar LoxP and LoxP-O sites
(in reverse complement), and accordingly the indels we
observed were similar (also in reverse complement) be-
tween the two constructs, despite one construct mediating
deletions and the other construct mediating inversions
(Additional file 1: Table S3). Thus, the identity and fre-
quency indels are likely specified by the sequences at the
cutting sites. It would be intriguing to study the molecular
mechanism underlying this exquisite sequence specificity.
NAG PAMs have not been considered in many CRISPR
off-target studies [34], whereas our assay detected signifi-
cant editing for sgLoxP and sgLoxP-O ‘NAG’ sites using
sensitive cellular reporters. Because of the much interest
in generating targeted chromosomal rearrangements using
CRISPR/Cas9, our observation of the suitability of using a
less favorable ‘NAG’ PAM to induce deletions suggests
the need for in-depth characterization of unwanted rear-
rangements between off-target sites with ‘NAG’ PAMs.
Notably, some variants of LoxP site such as Lox71 do not
contain the NAG PAM targeted by our sgRNA.
We tested three constructs (two inversions and one
deletion) by transfecting them into cell lines and noted
that the frequencies of error-free fusion were in the
range of 22–34 %. We also deleted and inverted a 50 kb
region of the Pten gene in mice, achieving 86 % and
100 % error-free fusions for deletion and inversion, re-
spectively. It appears that the repair of CRISPR/Cas9-
mediated inversion and deletion events are dependent
on the specific genomic sequences and sgRNAs used.
Conclusions
In summary, these fluorescent reporters can provide a
new method to rapidly quantify CRISPR-mediated DNA
rearrangements and underscore the importance of gen-
ome editing as a potential tool to study mechanisms of
chromosomal rearrangements.
Materials and methods
CRISPR vectors
sgRNA oligos were annealed and cloned into the pX330
vector using a standard BbsI protocol (Additional file 1:
Table S1).Purification of genomic DNA and the surveyor nuclease
assay
Genomic DNA was purified from mouse liver using
High Pure PCR Template Preparation Kit (Roche). For
the surveyor nuclease assay, PCR products were purified
with a QIAquick Gel Extraction Kit and treated with the
Surveyor nuclease kit (Transgenomic). DNA was elec-
trophoresed on a 4 % to 20 % Novex TBE Gel (Life
Technologies) with ethidium bromide staining. PCR
products of LoxP regions were cloned using Zero Blunt
TOPO PCR Cloning Kits (Life Technologies) and se-
quenced by the Sanger method [12].
Deep sequencing of CRISPR modified chromosomal
rearrangements
Inverted or deleted DNA regions were PCR amplified
using Herculase II high-fidelity polymerase and PCR
purified using a QIAquick Gel Extraction Kit. Libraries
were made from the PCR products using the Nextera
XT protocol [12] and sequenced on Illumina MiSeq
(250 bp paired-end). Data were processed according to
standard Illumina sequencing analysis procedures [12].
Reads were mapped to the reference sequences from
predicted genomic inversion or deletion events. Inser-
tions and deletions were called using VarScan2. Pten,
p53, and Ctnnb1 indels were analyzed using published
deep sequencing dataset [12].
Cell culture and transfection
Cell culture conditions were as described [12]. A total of
293T and mouse cells were transfected in 24-well plates
using Mirus LT1 or Lipo3000 reagents, respectively.
HCT116 cells were transfected with Lipofectamine 2000.
GFP images were acquired at 24 to 72 h (20X lens) and
total cellular DNA was harvested using QuickExtract re-
agent. For luminescence assay, cells were incubated with
30 mg/mL luciferin at a 1:200 dilution and assayed using
a Tecan plate reader. FACS was performed on an Accuri
C6 Flow Cytometer (BD). All data are representative of
at least two independent transfections.
Animal experiments
All animal study protocols were approved by the University
of Massachusetts institutional animal care and use com-
mittee. pX330.Pten.a and pX330.Pten.b DNA (30 μg each)
were delivered to approximately 8 week-old female FVB/
NJ mice (Jackson Laboratories) by hydrodynamic tail vein
injection. Plasmid DNA were purified using the EndoFree-
Maxi Kit (Qiagen). An equal amount of sgGFP or single
Pten sgRNA was used as controls.
Immunohistochemistry
Mice were humanely euthanized by CO2 asphyxiation.
Livers were fixed in 4 % or 10 % formalin overnight and
Li et al. Genome Biology  (2015) 16:111 Page 10 of 11embedded in paraffin. Liver sections of 4 μm were stained
with hematoxylin and eosin (H&E) or standard immuno-
histochemistry protocols using an anti-Pten antibody (Cell
Signaling). The number of hepatocytes was quantified
from >3 low-magnification fields per mouse with five mice
per group.
In vitro transcription of sgRNA
DNA templates carrying a T7 promoter was PCR-
generated from pX330 plasmids using Herculase II Fu-
sion DNA Polymerase (Agilent), ethanol precipitated,
and in vitro transcribed with in house made rNTPs, T7
buffer, and T7 polymerase. After 2 h of incubation at
37 °C, 50 U of TurboDNase (Life Technologies) was
added and incubated for 30 min at 37 °C. The reactions
were stopped with half a volume of formamide loading
buffer, and was followed by heat denaturation step for
5 min at 95 °C. Eight percent PAGE-Urea gel was prepared
with SequaGel-Urea Gel system (National Diagnostics)
and pre-run at 25 W. A total of 400 uL of each samples
were loaded, run at 25 W for 1.5 h, visualized with UV
lamp set on short wavelength, and gel purified.
Plasmid DNA cleavage assay
Cas9 protein (NEB) and sgRNA were pre-incubated for
10 min at 37 °C according to NEB protocols. Circular or
linearized DNA was added and incubated for 1 h. Samples
were analyzed by 1 % agarose gel electrophoresis with
ethidium bromide.
Statistics
Student’s t-tests were used to determine P values.
Additional files
Additional file 1: Table S1. sgRNA target site sequences. Table S2.
Primer sequences. Table S3. Reference sequences. The sequences
corresponding to the forward primers are underlined. Primers and
amplicon length are indicated. Table S4. Mapping summary of deep
sequencing data.
Additional file 2: Figure S1. Schematic of CRISPR-mediated inversion
and deletion. Figure S2. sgRNA targeting LoxP-O sites (sgLoxP-O) mediates
inversion of iGFP reporter. Figure S3. Pten immunohistochemistry in control
mice (n = 5). Figure S4. Assessing off-target cutting of sgPten.a. Figure S5.
Biochemical mapping of Cas9 cleavage site for sgiGFP.2. Figure S6. Staggered
Cas9 cleavage can influence NHEJ in mouse cells.
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